肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 EHA/ESMO临床实践指南：多发性骨髓瘤的诊断，治疗和随访

2021-02-02 欧洲血液学协会 Ann Oncol . 2021 Feb 2

多发性骨髓瘤

2021年2月，欧洲血液学协会(EHA)联合欧洲肿瘤内科学会(ESMO)共同发布了多发性骨髓瘤的诊断，治疗和随访指南。指南主要内容涉及多发性骨髓瘤的诊断和分期，一线治疗，难治性/复发性疾病的治疗，浆细

中文标题：

2021 EHA/ESMO临床实践指南：多发性骨髓瘤的诊断，治疗和随访

英文标题：

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

发布机构：

欧洲血液学协会

发布日期：

2021-02-02

简要介绍：

2021年2月，欧洲血液学协会(EHA)联合欧洲肿瘤内科学会(ESMO)共同发布了多发性骨髓瘤的诊断，治疗和随访指南。指南主要内容涉及多发性骨髓瘤的诊断和分期，一线治疗，难治性/复发性疾病的治疗，浆细胞白血病的管理，支持治疗以及随访等。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 EHA_ESMO临床实践指南：多发性骨髓瘤的诊断，治疗和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=cdcd31c00206a0ac, title=2021 EHA/ESMO临床实践指南：多发性骨髓瘤的诊断，治疗和随访, enTitle=Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, guiderFrom=Ann Oncol . 2021 Feb 2, authorId=0, author=, summary=2021年2月，欧洲血液学协会(EHA)联合欧洲肿瘤内科学会(ESMO)共同发布了多发性骨髓瘤的诊断，治疗和随访指南。指南主要内容涉及多发性骨髓瘤的诊断和分期，一线治疗，难治性/复发性疾病的治疗，浆细, cover=https://img.medsci.cn/2021223/1614011814186_2020535.jpg, journalId=0, articlesId=null, associationId=1164, associationName=欧洲血液学协会, associationIntro=欧洲血液学协会(European Haematology Association, EHA)旨在促进血液学领域的诊治、研究和教育, 目前拥有来自世界各地的成员4000多名。学会工作主要是组织年会、制定教育计划、出版刊物、宣传普及血液学学术成果, 进而促进欧洲内外血液病学专家学者的研究。, copyright=0, guiderPublishedTime=Tue Feb 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年2月，欧洲血液学协会(EHA)联合欧洲肿瘤内科学会(ESMO)共同发布了多发性骨髓瘤的诊断，治疗和随访指南。指南主要内容涉及多发性骨髓瘤的诊断和分期，一线治疗，难治性/复发性疾病的治疗，浆细胞白血病的管理，支持治疗以及随访等。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=321, tagName=多发性骨髓瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=321, guiderKeyword=多发性骨髓瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7359, appHits=278, showAppHits=0, pcHits=1525, showPcHits=7081, likes=3, shares=24, comments=17, approvalStatus=1, publishedTime=Tue Feb 23 00:55:10 CST 2021, publishedTimeString=2021-02-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Feb 23 00:37:01 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 21:38:02 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EHA_ESMO临床实践指南：多发性骨髓瘤的诊断，治疗和随访.pdf)])
2021 EHA_ESMO临床实践指南：多发性骨髓瘤的诊断，治疗和随访.pdf
下载请点击：
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2188167, encodeId=fb49218816ea5, content=学到了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=406b9177560, createdName=ms4000001945734419, createdTime=Mon Feb 19 16:38:57 CST 2024, time=2024-02-19, status=1, ipAttribution=河南), GetPortalCommentsPageByObjectIdResponse(id=973922, encodeId=d9169e3922ec, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44755410700, createdName=ms1283896697, createdTime=Tue Jun 15 23:25:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966214, encodeId=d08b966214ba, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Mon May 17 10:58:04 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963910, encodeId=d7f8963910b8, content=看不懂，有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f0c5495440, createdName=ms8000001534447968, createdTime=Sun May 09 09:55:18 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958074, encodeId=79cf9580e431, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 18 19:52:09 CST 2021, time=2021-04-18, status=1, ipAttribution=)]
    2024-02-19 ms4000001945734419 来自河南

    学到了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2188167, encodeId=fb49218816ea5, content=学到了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=406b9177560, createdName=ms4000001945734419, createdTime=Mon Feb 19 16:38:57 CST 2024, time=2024-02-19, status=1, ipAttribution=河南), GetPortalCommentsPageByObjectIdResponse(id=973922, encodeId=d9169e3922ec, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44755410700, createdName=ms1283896697, createdTime=Tue Jun 15 23:25:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966214, encodeId=d08b966214ba, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Mon May 17 10:58:04 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963910, encodeId=d7f8963910b8, content=看不懂，有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f0c5495440, createdName=ms8000001534447968, createdTime=Sun May 09 09:55:18 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958074, encodeId=79cf9580e431, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 18 19:52:09 CST 2021, time=2021-04-18, status=1, ipAttribution=)]
    2021-06-15 ms1283896697

    学习了#学习#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2188167, encodeId=fb49218816ea5, content=学到了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=406b9177560, createdName=ms4000001945734419, createdTime=Mon Feb 19 16:38:57 CST 2024, time=2024-02-19, status=1, ipAttribution=河南), GetPortalCommentsPageByObjectIdResponse(id=973922, encodeId=d9169e3922ec, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44755410700, createdName=ms1283896697, createdTime=Tue Jun 15 23:25:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966214, encodeId=d08b966214ba, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Mon May 17 10:58:04 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963910, encodeId=d7f8963910b8, content=看不懂，有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f0c5495440, createdName=ms8000001534447968, createdTime=Sun May 09 09:55:18 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958074, encodeId=79cf9580e431, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 18 19:52:09 CST 2021, time=2021-04-18, status=1, ipAttribution=)]
    2021-05-17 1903329706

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2188167, encodeId=fb49218816ea5, content=学到了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=406b9177560, createdName=ms4000001945734419, createdTime=Mon Feb 19 16:38:57 CST 2024, time=2024-02-19, status=1, ipAttribution=河南), GetPortalCommentsPageByObjectIdResponse(id=973922, encodeId=d9169e3922ec, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44755410700, createdName=ms1283896697, createdTime=Tue Jun 15 23:25:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966214, encodeId=d08b966214ba, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Mon May 17 10:58:04 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963910, encodeId=d7f8963910b8, content=看不懂，有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f0c5495440, createdName=ms8000001534447968, createdTime=Sun May 09 09:55:18 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958074, encodeId=79cf9580e431, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 18 19:52:09 CST 2021, time=2021-04-18, status=1, ipAttribution=)]
    2021-05-09 ms8000001534447968

    看不懂，有中文吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2188167, encodeId=fb49218816ea5, content=学到了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=406b9177560, createdName=ms4000001945734419, createdTime=Mon Feb 19 16:38:57 CST 2024, time=2024-02-19, status=1, ipAttribution=河南), GetPortalCommentsPageByObjectIdResponse(id=973922, encodeId=d9169e3922ec, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44755410700, createdName=ms1283896697, createdTime=Tue Jun 15 23:25:59 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966214, encodeId=d08b966214ba, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Mon May 17 10:58:04 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963910, encodeId=d7f8963910b8, content=看不懂，有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f0c5495440, createdName=ms8000001534447968, createdTime=Sun May 09 09:55:18 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958074, encodeId=79cf9580e431, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 18 19:52:09 CST 2021, time=2021-04-18, status=1, ipAttribution=)]
    2021-04-18 446993560

    期待

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2021 IMWG建议：多发性骨髓瘤相关骨病的治疗

国际骨髓瘤工作组(IMWG,International Myeloma Working Group) · 2021-02-02

2020 EMN共识建议：多发性骨髓瘤的疫苗接种

欧洲骨髓瘤网络(EMN,European Myeloma Network) · 2020-08-19

中国多发性骨髓瘤诊治指南（2020年修订）

中国医师协会血液科医师分会 · 2020-05-25

2020 共识建议：应用塞利尼索治疗多发性骨髓瘤患者的管理

国外血液科相关专家小组 · 2020-03-07

2020 MCRN共识指南：多发性骨髓瘤及相关疾病的诊断

国外血液科相关专家小组 · 2020-02-04

拓展阅读

2015 IMWG 多发性骨髓瘤患者管理中MRI应用的共识声明

国际骨髓瘤工作组(IMWG,International Myeloma Working Group) · 2015-01-20

2015 ASBMT指南：造血干细胞移植治疗多发性骨髓瘤

美国血液与骨髓移植学会(ASBMT,American Society for Blood and Marrow Transplantation) · 2015-03-10

中国多发性骨髓瘤诊治指南（2015年修订）

中国医师协会血液科医师分会 · 2015-12-01

多发性骨髓瘤周围神经病变诊疗中国专家共识（2015年）

中国医师协会血液科医师分会 · 2015-09-08

2016 新加坡骨髓瘤研究组共识指南：多发性骨髓瘤患者的管理

新加坡骨髓瘤研究组(Singapore Myeloma Study Group) · 2016-09-09

2016 SIN立场声明：体外轻链去除技术治疗多发性骨髓瘤导致的急性肾损伤

意大利肾病学会(SIN,Italian Society of Nephrology) · 2016-10-18